Loading clinical trials...

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

A Phase I Study to Evaluate Safety and Pharmacokinetics of SAR408701 Administered Intravenously as Monotherapy in Japanese Patients With Advanced Malignant Solid Tumors

NCT03324113•Sanofi

View on ClinicalTrials.gov

Summary

Primary Objective: * To evaluate tolerability and safety of SAR408701 when administered as a single agent according to the investigational medicinal product (IMP) related dose limiting toxicities (DLTs) to determine the recommended dose (RD) of SAR408701 in Japanese patients with advanced malignant solid tumors. Secondary Objectives: * To characterize the overall safety profile of SAR408701 monotherapy. * To characterize the pharmacokinetic (PK) profile of SAR408701 and its metabolites. * To evaluate the pharmacodynamic (PDy) effect of SAR408701 on levels of circulating carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for main dose escalation part. * To assess preliminary efficacy according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 criteria and other indicators of antitumor activity. * To assess the potential immunogenicity of SAR408701.

Detailed Description

The study duration per participant will include a period to assess eligibility (screening period) of up to approximately 4 weeks (28 days), a treatment period and an End-of-Treatment (EOT) visit around 30 days after the last administration of IMP, and at least one follow-up (FU) visit after the EOT visit.

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Locally advanced or metastatic solid malignant tumor disease for which, in the judgement of the investigator, no standard alternative therapy is available.
•Inclusion is likely to be expressing CEACAM5.
•At least 6 x 5 μm slides from formalin-fixed paraffin-embedded (FFPE) archival tissue should be available for retrospective central evaluation of CEACAM5 expression.
•Patient understands and has signed the Written Informed Consent form and is willing and able to comply with the requirements of the trial.

Exclusion Criteria

•Patient less than 20 years old.
•Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2.
•Life expectancy \<12 weeks.
•Known or symptomatic brain metastasis (other than totally resected or previously irradiated and non-progressive/relapsing) or lepto-meningeal carcinomatosis.
•Female patients of childbearing potential and male patients with female partners of childbearing potential who do not agree to use accepted and effective method of contraception during the study treatment period and for 6 months following discontinuation of IMP.
•Significant concomitant illnesses, including all severe medical conditions which, in the opinion of the Investigator or Sponsor, would impair the patient's participation in the study or interpretation of the results.
•Prior therapy targeting CEACAM5.
•Prior maytansinoid treatments (maytansinoid derivative 1 \[DM1\] or maytansinoid derivative 4 \[DM4\] antibody drug conjugates).
•Previous history and or unresolved corneal disorders.
•Medical conditions requiring concomitant administration of medications with narrow therapeutic window, metabolized by cytochrome P450 (CYP) and for which a dose reduction cannot be considered.
+2 more criteria

Locations (3)

Investigational Site Number : 3920002

Nagoya, Aichi-ken, Japan

Investigational Site Number : 3920003

Kashiwa-shi, Chiba, Japan

Investigational Site Number : 3920001

Sunto-gun, Shizuoka, Japan

Key Dates

Start Date

October 17, 2017

Primary Completion Date

November 18, 2022

Completion Date

December 26, 2022

Last Updated

August 5, 2025

Enrollment

ACTUAL participants

Conditions

Neoplasm Malignant

Interventions

SAR408701

DRUG

dexamethasone

DRUG

naphazoline

DRUG

diphenhydramine

DRUG

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

NCT07209111

Neoplasm Malignant

View study

RECRUITINGNA

TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography

NCT06310330

Breast Neoplasm Malignant Primary

View study

RECRUITINGPHASE2

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

NCT05247268

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

Inclusion Criteria

Exclusion Criteria

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

Study of the Impact of DPD Activity on the Efficacy of Capecitabine

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)